La NASA, la agencia espacial líder en el mundo, ha estado a la vanguardia de la exploración espacial durante décadas. Desde el histórico aterrizaje en la Luna en 1969 hasta las misiones más recientes a Marte, la NASA ha demostrado una y otra vez su capacidad para i …
Transgene and BioInvent International AB announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, announced that over 400,000 of its ADRs are now outstanding.
IRLAB Therapeutics IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has secured top expertise in supporting the preparations for Phase III with mesdopetam.
Genentech, a member of the Roche Group, announced positive topline long-term results from the global Phase III BALATON and COMINO studies evaluating extended treatment intervals with Vabysmo® in macular edema due to branch and central retinal vein occlusion.
CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC, announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa region.
Acurex Biosciences Corporation has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J. Fox Foundation.
AstriVax is pleased to announce that Dr. Mathieu Peeters and Barbara Freitag have joined the company’s leadership team as Chief Development Officer and Chief Financial Officer, respectively.
Descripción general sobre el manejo inicial de la emergencia por tumores sólidos
Guía para la atención primaria | Fundamentos de oncología aguda Read More »
Nearly half of all companies with CRM would say, “it doesn’t live up to the hype.”
Bad CRM data can cost your MedTech company 10% in annual revenue Read More »
